Fortuny Joan, de Sanjosé Sílvia, Becker Nikolaus, Maynadié Marc, Cocco Pier Luigi, Staines Anthony, Foretova Lenka, Vornanen Martine, Brennan Paul, Nieters Alexandra, Alvaro Tomàs, Boffetta Paolo
Servei d'Epidemiologia i Registre del Càncer, Institut Català d'Oncologia, Gran Via Km 2.7, 08907 L'Hospitalet de Llobregat, Autonomous University of Barcelona [corrected] Barcelona, Catalonia, Spain.
Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):921-5. doi: 10.1158/1055-9965.EPI-05-0866.
Statins, drugs used to treat dyslipidemia, may have anticancer properties. We have evaluated lymphoma risk associated with regular statin use in an international case-control study.
This case-control study included 2,362 cases of incident B- and T-cell lymphoma from Czech Republic, France, Germany, Ireland, Italy, and Spain and 2,206 hospital or population controls. Information on drug use, diagnosis at admission (for hospital controls), and putative risk factors for lymphoma was collected with personal interviews. Hospital controls admitted for diseases possibly entailing use of statins were excluded from the analysis.
The odds ratio for regular statin use was 0.61 (95% confidence interval, 0.45-0.84); all major lymphoma subtypes showed similarly decreased risks. Decreased risks were observed in all centers. Duration of statin use was not associated with a greater reduction in the risk of lymphoma. Use of other lipid lowering drugs, such as fibrates, did not significantly modify the risk of lymphoma (odds ratio, 0.75; 95% confidence interval, 0.44-1.27).
Statin use was associated with an important reduction in lymphoma risk, adding to the growing evidence of anticancer properties of this group of drugs. These results are reassuring for the increasing number of patients taking statins on a regular basis.
他汀类药物用于治疗血脂异常，可能具有抗癌特性。我们在一项国际病例对照研究中评估了常规使用他汀类药物与淋巴瘤风险之间的关联。
这项病例对照研究纳入了来自捷克共和国、法国、德国、爱尔兰、意大利和西班牙的2362例新发B细胞和T细胞淋巴瘤病例以及2206例医院对照或人群对照。通过个人访谈收集药物使用信息、入院时的诊断（针对医院对照）以及淋巴瘤的假定危险因素。因可能需要使用他汀类药物的疾病而入院的医院对照被排除在分析之外。
常规使用他汀类药物的比值比为0.61（95%置信区间，0.45 - 0.84）；所有主要淋巴瘤亚型的风险均有类似程度的降低。在所有中心均观察到风险降低。他汀类药物的使用时长与淋巴瘤风险的更大降低无关。使用其他降脂药物，如贝特类药物，并未显著改变淋巴瘤风险（比值比，0.75；95%置信区间，0.44 - 1.27）。
使用他汀类药物与淋巴瘤风险的显著降低相关，这进一步证明了这类药物具有抗癌特性。这些结果对于越来越多定期服用他汀类药物的患者来说是令人安心的。
